/Investor DB

Foresite Capital — Full Portfolio

242 tracked investments · page 1 of 2 · listed companies and verified rows first

Alumisalumis.comin𝕏NASDAQ: ALMSSeries A · Jul 2024 · $70M

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in

Board seatJames Tananbaum· per SEC Form D

Co-investorsGeneral AtlanticHBM Healthcare InvestmentsHBM PartnersNextech InvestOrbiMedSamsara BioCapital+4 more

Fulcrum TherapeuticsinNASDAQ: FULCAug 2018

Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.

BiotechCambridge, US

Robert Gould(Executive Officer, Director)inAlex C. Sapir(President and Chief Executive Officer, Director)in

BoardAlan Ezekowitz(Director)inMark Levin(Director)inJames Geraghty(Director)James Collins(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsSanofi VenturesThird Rock Ventures

10x Genomics10xgenomics.comin𝕏NASDAQ: TXGMay 2019

10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers.

BiotechDeep TechHardwareHealthtechPleasanton, US

Serge Saxonov(Founder)inBen Hindson(Founder)inBrad Crutchfield(Chief Commercial Officer)Jean Philibert(Chief People Officer)Eric S Whitaker(General Counsel)inJustin McAnear(Chief Financial Officer)

Co-investorsFoothill VenturesKhosla VenturesOMX VenturesPaladin Capital GroupSoftBank Vision FundVenrock+4 more

Aclaris Therapeuticsaclaristx.comNASDAQ: ACRS

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)inHugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)

Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalRA CapitalSofinnova VenturesSofinnova Venture Partners+1 more

Adagio TherapeuticsNASDAQ: IVVDApr 2021 · $336M

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Co-investorsGV (Google Ventures)Fidelity InvestmentsMithril Capital ManagementOmega FundsOrbiMedPolaris Partners+3 more

Adaptimmuneadaptimmune.comin𝕏OTC: ADAPYSep 2014

Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.

BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US

James Noble(Chief Executive Officer)Adrian Rawcliffe(Chief Executive Officer and Director)inGavin Wood(Chief Financial Officer)inWilliam Bertrand(Chief Operating Officer)inJohn Lunger(Chief Patient Supply Officer)inElliot Norry(Chief Medical Officer)in

Co-investorsAvoro Capital AdvisorsEight Roads VenturesF-Prime CapitalNew Enterprise Associates (NEA)Ridgeback Capital

Adaptive Biotechnologiesadaptivebiotech.comin𝕏NASDAQ: ADPT

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US

Chad Robins(Chief Executive Officer, Co-founder, Chairman of the Board)inHarlan Robins(Co-founder; Chief Scientific Officer until 2026)inKathleen Determann(Executive Officer)inDean Schorno(Executive Officer)inChris Carlson(Executive Officer)Kyle Piskel(Chief Financial Officer)in

Co-investorsDecheng CapitalFMG CapitalKhosla VenturesViking GlobalCasdin CapitalOrbiMed

Adicet Bioadicetbio.comNASDAQ: ACET

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in

BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)

Co-investorsOrbiMedPontifax Venture CapitalQuan CapitalaMoonNovartis Venture FundPureTech Health

Alectoralector.comin𝕏NASDAQ: ALECSep 2015

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)

BoardCarl Gordon(Director)Terry McGuire(Director)in

Co-investorsGV (Google Ventures)Mission Bay CapitalMission BiocapitalMRL Ventures FundSV Health InvestorsPolaris Partners

Allogene Therapeuticsallogene.comin𝕏NASDAQ: ALLOApr 2018

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Arie Belldegrun, M.D.(Executive Chairman and Co-Founder)inDavid Chang, M.D., Ph.D.(Co-Founder, Allogene)Christine Cassiano(Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer and one of the founders)inZachary Roberts, M.D., Ph.D.(President and Chief Executive Officer)ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Co-Founder and Director of Allogene)

Co-investorsAvoro Capital AdvisorsTPGVida VenturesGilead Sciences

Alx Oncologyalxoncology.comin𝕏NASDAQ: ALXO

ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.

BiotechHealthtechMedical Devices

Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in

Co-investorsLightstone Venturesage1HBM Healthcare InvestmentsHBM PartnersvenBio PartnersLogos+1 more

Arbutus Biopharma Corporationarbutusbio.cominNASDAQ: ABUSDec 2016

Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development.

BiotechHealthtechWarminster, US

William H. Collier(President and Chief Executive Officer)inGaston Picchio(Chief Development Officer)inMichael J. McElhaugh(Chief Business Officer)inDavid C. Hastings(Chief Financial Officer)inMichael J. Sofia(Chief Scientific Officer)inElizabeth Howard(Executive Officer)in

Aura Biosciencesaurabiosciences.comin𝕏NASDAQ: AURA

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsAdvent Life SciencesChiesi VenturesColumbus Venture PartnersDroia VenturesJazzya InvestmentsMedicxi+6 more

Beam Therapeuticsbeamtx.comin𝕏NASDAQ: BEAMNov 2018

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

David R. Liu(Founder)inJ. Keith Joung(Founder)inFeng Zhang(Founder)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)

Co-investorsARCH Venture PartnersDreamers VCEight Roads VenturesF-Prime CapitalGV (Google Ventures)HongShan Capital Group+2 more

Bicara Therapeuticsbicara.comin𝕏NASDAQ: BCAX

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.

Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDavid Raben(Chief Medical Officer)in

Co-investorsAisling CapitalEight Roads VenturesF-Prime CapitalPremji InvestRA CapitalRed Tree Venture+6 more

Casi Pharmaceuticalscasipharmaceuticals.cominOTC: CASIF

CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells.

BiotechHealthtechBeijing

Chunhua Wang(Chief Operating Officer)Wei Gao(General Counsel)Hai Huang(Global Chief Commercial Officer)Alexander A. Zukiwski(Chief Medical Officer)Wei (Larry) Zhang(President)Wei-Wu He(Chief Executive Officer, Chairman of the Board of Directors)

Celldex Therapeutics, Inc.celldex.comin𝕏NASDAQ: CLDXNov 2016

Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation.

BiotechHealthtechHampton, US

Anthony S. Marucci(Executive Officer, Director)inAvery W. Catlin(Executive Officer)

BoardRichard van den Broek(Director)Timothy M. Shannon, M. D.(Director)Herbert J. Conrad(Director)Karen Shoos(Director)

CG Oncologycgoncology.comin𝕏NASDAQ: CGONAug 2023 · $110M

CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.

BiotechHealthtechMedical Devices

Arthur Kuan(Chairman and Chief Executive Officer)in

Co-investorsDecheng CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG CrossoverACORN BIOVENTURES+3 more

Compass Therapeuticscompasstherapeutics.comin𝕏NASDAQ: CMPXDec 2017

Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.

BiotechHealthtechCambridge, US

Schuetz Thomas(Executive Officer, Director)inErrik Anderson(Executive Officer, Director)inThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNeil Lerner(Senior Vice President, Chief Accounting Officer)in

Co-investorsAlumni VenturesBioBritF-Prime CapitalGV (Google Ventures)OrbiMedvenBio Partners+3 more

Crinetics Pharmaceuticalscrinetics.comin𝕏NASDAQ: CRNX

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)Stephen Betz(Chief Scientific Officer)inR. Scott Struthers(President, Chief Executive Officer and Director)inTobin Schilke(Chief Financial Officer)inIsabel Kalofonos(Chief Commercial Officer)inYunFei Zhu(Executive Officer)

Co-investors5AM VenturesOrbiMedRA CapitalVivo Capital

Cullinan Therapeuticscullinantherapeutics.com𝕏NASDAQ: CGEM

Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.

BiotechHealthtechMedical Devices

Mary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)Jennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNadim Ahmed(President and Chief Executive Officer)in

Co-investorsNextech InvestBiotechnology Value FundOrbiMed

Cytokineticscytokinetics.comin𝕏NASDAQ: CYTK

Cytokinetics develops potential medicines for cardiovascular and neuromuscular diseases characterized by impaired muscle function.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

James SpudichinRonald ValeLawrence S.B. GoldsteinRobert I. Blum(President and Chief Executive Officer)in

BoardJames Sabry

Denali Therapeuticsdenalitherapeutics.cominNASDAQ: DNLIFeb 2024

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

Marc Tessier-Lavigne(Founder)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)inAlexander Schuth(Founder)

Co-investorsARCH Venture PartnersEcoR1 CapitalF-Prime CapitalGV (Google Ventures)Flagship PioneeringFlagship Ventures

Disc Medicinediscmedicine.comin𝕏NASDAQ: IRON

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in

Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesFrazier Life SciencesOrbiMed5AM Ventures+7 more

Edgewise Therapeuticsedgewisetx.comin𝕏NASDAQ: EWTX

Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

BiotechDigital HealthBoulder, US

Kevin Koch(Executive Officer, Director)inAlan Russell(Director)inBadreddin Edris(Director and Co-Founder)inKenneth Harrison(Director)

BoardPeter Thompson(Director)inJonathan Root(Director)in

Co-investorsBoulder VenturesOrbiMedUS Venture PartnersViking GlobalWellington ManagementDeerfield Management Company+1 more

GH Researchghres.comNASDAQ: GHRS

A pharmaceutical company whose executive team emphasizes innovation and patient care.

BiotechDigital HealthMental Health

Co-investorsRA Capital

Grailgrail.comin𝕏NASDAQ: GRAL

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)inRichard Klausner(Director)

Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+13 more

Hinge Healthhingehealth.comin𝕏NYSE: HNGE

Hinge Health builds a digital healthcare platform designed to help individuals manage musculoskeletal health and related conditions.

Digital HealthHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Gabriel Mecklenburg(Founder)inDaniel Perez(Founder)inKevin McCullough(Founder)Shaun Rahimi(Founder)

Co-investors11.2 CapitalAlkeon InnovationAtomicoBessemer Venture PartnersCannage CapitalCoatue Management+16 more

Insmedinsmed.comin𝕏NASDAQ: INSM

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

Will Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSara Bonstein(Chief Financial Officer)inRoger Adsett(Chief Operating Officer)Martina Flammer(Chief Medical Officer)inS. Nicole Schaeffer(Chief People Strategy Officer)in

Co-investorsBessemer Venture PartnersF-Prime CapitalHercules Capital, Inc.OrbiMedProspect Venture PartnersRidgeback Capital+1 more

Intellia Therapeuticsintelliatx.comin𝕏NASDAQ: NTLAAug 2015

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsage1Atlas VentureAvoro Capital AdvisorsEcoR1 CapitalOrbiMedRidgeback Capital+1 more

Invivydinvivyd.comin𝕏NASDAQ: IVVD

Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsBain Capital Life SciencesMRL Ventures FundPremji InvestRA CapitalGV (Google Ventures)Mithril Capital Management+2 more

Keros Therapeuticskerostx.cominNASDAQ: KROS

Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.

BiotechHealthtechLexington, US

Jasbir Seehra(Co-Founder, Chief Executive Officer and Director)in

BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in

Co-investorsArkin CapitalOrbiMedPontifax Venture Capital

Kura Oncologykuraoncology.cominNASDAQ: KURA

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

PINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy Wilson, Ph.D., J.D.(Co-founder; President, Chief Executive Officer and Chairman of the Board)Kevan M. Shokat, Ph.D.(Founding team member)HEIDI HENSON(Executive Officer)in

Co-investorsARCH Venture PartnersAvoro Capital AdvisorsEcoR1 CapitalNextech InvestOUP (Osage University Partners)

Madrigalmadrigalpharma.comin𝕏NASDAQ: MDGLApr 2016

Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).

BiotechHealthtechMedical DevicesConshohocken, US

Rebecca Taub(Founder and Director)inMarc R. Schneebaum(Executive Officer)inPaul A. Friedman(Executive Officer, Director)inBill Sibold(President and Chief Executive Officer)inMardi Dier(Executive Vice President and Chief Financial Officer)inCarole Huntsman(Executive Vice President and Chief Commercial Officer)in

Co-investorsAvoro Capital AdvisorsBay City Capital

Maze Therapeuticsmazetx.comin𝕏NASDAQ: MAZEFeb 2019

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in

Co-investorsAndreessen HorowitzARCH Venture PartnersFrazier Life SciencesGV (Google Ventures)Hercules Capital, Inc.Alexandria+9 more

Nateranatera.comin𝕏NASDAQ: NTRA

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)

Co-investorsBain Capital Life SciencesCheyenne VenturesClaremont Creek VenturesHarmony PartnersHBM Healthcare InvestmentsLightspeed Venture Partners+4 more

Olema Pharmaceuticalsolema.comin𝕏NASDAQ: OLMA

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)inShane Kovacs(Executive Officer)in

Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesLightspeed Venture PartnersRA CapitalWellington ManagementBiotechnology Value Fund+2 more

Omeros Corp.omeros.comNASDAQ: OMER

Omeros is a publicly traded biotech company developing a diverse pipeline of first-in-class small-molecule and antibody therapeutics targeting unmet medical needs across multiple therapeutic areas and indications.

BiotechHealthtechMedical DevicesSeattle, US

Co-investorsSPRINGROCK VENTURES

Parabilis Medicinesparabilismed.cominNASDAQ: PBLS

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)in

Co-investorsARCH Venture PartnersCatalio Capital Management, LPFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM Healthcare Investments+9 more

Quince TherapeuticsNASDAQ: QNCX

Quince Therapeutics is a biotechnology company developing the AIDE technology platform, a drug/device combination that encapsulates medications into a patient's own red blood cells to improve drug delivery for rare diseases.

BiotechSouth San Francisco, US

Stephen Dominy(Director)Casey Lynch(Executive Officer, Director)Charles Ryan(Executive Officer)inBrendan Hannah(Executive Officer)Dirk Thye(Executive Officer, Director)inKristen Gafric(Executive Officer)

Co-investorsSofinnova PartnersTakeda Ventures

Relayrelaytx.comin𝕏NASDAQ: RLAYJan 2024

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.

AI & Machine LearningBiotechDeep TechCambridge, US

Donald A. Bergstrom(Executive Officer)inSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)

Co-investorsCommonweal VenturesEcoR1 CapitalNat TurnerNextech InvestSoftBank Vision FundCurie.Bio+2 more

Replimunereplimune.comin𝕏NASDAQ: REPL

Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.

BiotechHealthtechMedical Devices

Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)

Co-investorsAtlas VentureBain Capital Life SciencesREDMILE

Revolution Medicinesrevmed.cominNASDAQ: RVMD

Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.

BiotechHealthtechMedical DevicesRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)

Co-investorsBain Capital Life SciencesGen CapitalGV (Google Ventures)Illinois VenturesNextech InvestThe Column Group+2 more

Rxsightrxsight.comin𝕏NASDAQ: RXST

RxSight is an ophthalmic medical technology company that developed the Light Adjustable Lens (LAL), an intraocular lens that can be customized after cataract surgery to optimize a patient's vision.

HardwareHealthtechMedical DevicesPasadena, US

Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRon Kurtz(Chief Medical Officer (former President & CEO))Mark Wilterding(Chief Financial Officer)in

Co-investorsFlying L PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude CapitalRA CapitalVisionary Ventures+2 more

Scynexisscynexis.comin𝕏NASDAQ: SCYX

SCYNEXIS is a biopharmaceutical company focused on developing drug therapies for severe rare diseases, including anti-infective and antifungal treatments.

BiotechMedical DevicesDurham, US

Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)inDavid Angulo(President & Chief Executive Officer)inEric Sukenick(General Counsel)Sanjay Subramanian(Chief Financial Officer)

Co-investorsDecheng CapitalDeerfield Management CompanyRA Capital

Seaport Therapeuticsseaporttx.comin𝕏NASDAQ: SPTXOct 2024

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO & Board Member)inSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)Michael Chen(Executive Officer)inLana Gladstein(Executive Officer)inAntony Loebel(Executive Officer)in

Co-investorsARCH Venture PartnersGeneral AtlanticHAWKTAILPureTech HealthSofinnova VenturesCPP Investments+3 more

Silence Therapeuticssilence-therapeutics.comNASDAQ: SLNFeb 2021

Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.

BiotechLondon

Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)

BoardJames Ede-Golightly(Director)Alistair Gray(Director)

Co-investorsMC Healthcare VenturesNextech InvestVivo Capital

Solid Biosciencessolidbio.comin𝕏NASDAQ: SLDB

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.

BiotechHealthtechCharlestown, US

Ilan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)Carl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)Martin Freed(Director)inPaul Herizch(Executive Officer)

Co-investorsBain Capital Life SciencesRA CapitalBain Capital

SUTROVAX, INC.sutrovax.comNASDAQ: PCVX

Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.

BiotechDeep TechHealthtechSouth San Francisco, US

Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in

Co-investorsAbingworthCTI Life Sciences Fund L.P.Frazier Life SciencesJanus Henderson InvestorsLongitude CapitalMedicxi+4 more

Syndax Pharmaceuticalssyndax.cominNASDAQ: SNDX

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in

BoardDennis Podlesak(Director)inIvor Royston(Director)

Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 Capital+6 more

Tango Therapeuticstangotx.comNASDAQ: TNGX

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

Alan Huang(Executive Officer)inAdam Crystal(Executive Officer)inDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)

BoardBarbara Weber(Executive Officer, Director)in

Co-investorsNextech InvestNSG VenturesThird Rock Ventures

Vaxcytevaxcyte.comNASDAQ: PCVX

Vaxcyte is a clinical-stage biotechnology company developing vaccines to prevent or treat bacterial infectious diseases, including pneumococcal conjugate vaccine candidates.

BiotechHealthtech

Grant Pickering(Chief Executive Officer, Director and Co-Founder)inJeff Fairman(Vice President of Research and Co-Founder)

Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Frazier Life SciencesLongitude CapitalPivotal Life SciencesRA Capital+3 more

Verastemverastem.comin𝕏NASDAQ: VSTM

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)inCATHY CAREW(Executive Officer)inJONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in

Co-investorsBessemer Venture PartnersCardinal PartnersLightstone VenturesLongwood FundOberland CapitalViking Global+1 more

Wave Life Scienceswavelifesciences.comin𝕏NASDAQ: WVE

Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.

BiotechHealthtechLongevitySingapore, US

Takeshi Wada(Director)inGregory L. Verdine(Director)Paul B. Bolno, M.D.(Executive Officer, Director)inPaul Bolno, MD, MBA(President and Chief Executive Officer, Wave Life Sciences)

BoardPeter Kolchinsky(Director)inKen Takanashi(Director)

Co-investorsRA CapitalAescap Life Sciences

Xenon Pharmaceuticalsxenon-pharma.comin𝕏NASDAQ: XENE

Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders.

BiotechHealthtech

Ian Mortimer(President and Chief Executive Officer)inDarren Cline(Chief Commercial Officer)inAndrea DiFabio(Chief Legal Officer and Corporate Secretary)inJames Empfield(Executive Vice President, Drug Discovery)inTucker Kelly(Chief Financial Officer)inChris Kenney(Chief Medical Officer)in

Co-investorsArcher Capital GroupArcher Venture CapitalAvoro Capital AdvisorsNew Enterprise Associates (NEA)

Remix Therapeuticsremixtx.comin𝕏Series A · Jan 2024 · $70M✓ verified

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)inMatthew Patterson(Director)inScott Biller(Director)in

Board seatMichael Rome· per SEC Form D

Co-investorsAtlas VentureThe Column GroupARCH Venture PartnersAlexandriaDecheng Capital

Bit Biobit.bioin𝕏Jun 2020 · $41.5M✓ verified

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.

BiotechDeep TechHealthtechMedical Devices

Dr Mark Kotter(Founder)Przemek Obloj(CEO)inEmma Pepperell(CEO)inMark Kotter(Founder)

Co-investorsBlueYard CapitalARCH Venture PartnersDynamk CapitalGood AI CapitalHarmonix FundHAWKTAIL+7 more

Cerevancecerevance.comin𝕏✓ verified

Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US

Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in

Co-investorsDementia Discovery FundGV (Google Ventures)SV Life SciencesDementia DiscoveryDolby Family VenturesLightstone Ventures+3 more

Curisiumhealthverity.comin𝕏✓ verified

HealthVerity operates a healthcare and consumer data ecosystem that enables HIPAA-compliant synchronization and exchange of real-world data across pharma, payers, and government agencies.

Data & InfrastructureEnterprise SoftwareHealthtechPhiladelphia, US

Andrew Kress(Co-Founder and CEO)inAndrew Goldberg(Co-Founder and COO)

BoardMichael Greeley(Director)inRachel Winokur(Director)

Co-investorsFlare Capital PartnersGreycroftNew Enterprise Associates (NEA)

Engrail Therapeuticsengrail.comin✓ verified

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsLongwood FundNorwest Venture PartnersPivotal Life SciencesRiverVest Venture PartnersYsios Capitalabrdn plc+4 more

Pleno Inc.plenoinc.comin✓ verified

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.

BiotechHardwareHealthtech

Co-investorsMedical Excellence CapitalDeerfield Management Company

Spearspear.bioin𝕏✓ verified

Spear Bio develops high-sensitivity immunoassays based on its SPEAR (Successive Proximity Extension Amplification Reaction) technology, which originated from research at the Wyss Institute.

BiotechHealthtechMedical Devices

Feng Xuan(Chief Executive Officer & Co-founder)Peng Yin(Director & Co-Founder)

Co-investorsMaverick VenturesYonghua Capital

Kinnate Biopharmakinnate.comSeries A · Dec 2019 · $22M

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)

Board seatMichael Rome· per SEC Form D

Co-investorsNextech InvestViking GlobalJanus Henderson InvestorsRA CapitalVenrock Healthcare Capital PartnersViking Global Investors

Pardes Biosciencespardesbio.cominSeries A · Feb 2021

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

BiotechHealthtechSan Francisco, US

Uri Lopatin(CEO)inUri A. Loptain(Executive Officer, Director)Heidi Henson(Executive Officer)inElizabeth Lacy(Executive Officer)Lee Arnold(Executive Officer)

BoardJ. Jay Lobell(Director)

Board seatJames B. Tananbaum· per SEC Form D

Co-investorsFrazier Life SciencesY CombinatorKhosla Ventures

Riskgamingriskgaming.cominFeb 2025

Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.

BiotechHayward, US

Kegan Schouwenburg(Executive Officer, Director)Roger M. Perlmutter(Executive Officer, Director)in

BoardJoshua Wolfe(Director)inDror Berman(Director)Leon Chen(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsBain Capital Life SciencesCisco InvestmentsLux CapitalDimension Capital

Tarsa Therapeuticstarsatherapeutics.comFeb 2016

Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.

BiotechPhiladelphia, US

David Brand(Executive Officer, Director)inGregory Lumpkin(Executive Officer)

BoardRichard Kollender(Director)Martin Edwards(Director)Eric Bednarski(Director)Derek Ferguson(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsMVM Life Science PartnersOxford Finance LLCQuaker BioVentures

Theseus Pharmaceuticalstheseusrx.comSeries B · Jun 2018 · $100M

BiotechCambridge, US

William C. Shakespeare(Director)in

BoardIain Dukes(Executive Officer, Director)inCarl Gordon(Director)in

Board seatMichael Rome· per SEC Form D

Co-investorsLongitude CapitalNextech InvestNexTech VenturesOmega FundsOrbiMedPontifax Venture Capital+2 more

Abcuroabcuro.comAug 2026

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+9 more

Acceleronacceleronpharma.comin𝕏Dec 2011

A pharmaceutical company that develops medicines and vaccines for patients globally.

BiotechHealthtechMedical DevicesCambridge, US

WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)inKEVIN F. MCLAUGHLIN(Executive Officer)inMATTHEW L. SHERMAN(Executive Officer)

Co-investorsBessemer Venture PartnersLightstone VenturesLowercarbon CapitalSofinnova VenturesVenrockCollaborative Fund

Aerie Pharmaceuticalsaeriepharma.cominSep 2014

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in

Co-investorsAlta PartnersAvoro Capital AdvisorsOUP (Osage University Partners)Sofinnova Ventures

Aetionaetion.com

Healthcare technology company delivering real-world evidence for life sciences companies, payers, and regulators.

Data & InfrastructureDigital HealthHealthtechNew York, US

Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Founder)Kyle Armbrester(Chief Executive Officer)inSebastian Schneeweiss(Founder)

Co-investorsB Capital GroupB4 CapitalBlue LionBlue Lion GlobalFlare Capital PartnersLG Technology Ventures+8 more

Affinivaxaffinivax.comin𝕏Series C · Jan 2021 · $230M

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsBain Capital Life SciencesEcoR1 CapitalViking GlobalBain CapitalRock Springs CapitalT. Rowe Price

Aimmune Therapeuticsaimmune.comAcquired

Aimmune Therapeutics developed desensitization treatments for life-threatening food allergies, including Palforzia, the first FDA-approved peanut allergy treatment.

Co-investorsAisling CapitalLongitude CapitalMenlo Ventures

Akeroakerotx.comin𝕏

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsAtlas VentureFrazier Life SciencesGeneral AtlanticLifeSci Venture PartnersScion Life SciencesThe Innovation Space+2 more

Altanaacceldata.ioin

Acceldata provides a unified platform for building, governing, and scaling data and AI workloads with end-to-end observability across pipelines.

AI & Machine LearningData & InfrastructureEnterprise SoftwarePalo Alto, US

Rohit Choudhary(Founder)inAshwin Rajeeva(Founder)inSatish Krishnamurthy(Executive Officer, Director)Maram Nagendraprasad(Executive Officer, Director)Gaurav Nagar(Founder)in

BoardDev Khare(Director)in

Co-investorsDrive CapitalEMERGENT VENTURESFelicis VenturesFocal VenturesGeneral CatalystInsight Partners+23 more

Ambit Biosciences Corporationambitbio.comacquired by Daiichi Sankyo · Oct 2014 · $315M

Ambit Biosciences was a San Diego biopharmaceutical company developing small-molecule kinase inhibitors, including quizartinib, a FLT3 inhibitor for acute myeloid leukemia.

Co-investorsAisling Capital

Apollo Health Venturesapollo.vcin𝕏Jan 2026

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

Nils Regge(Co-Founder & General Partner)in

Co-investorsBLN CapitalCoastCapFJ LabsKfW CapitalQuery CapitalTruVenturo GmbH+4 more

Arcus Biosciencesarcusbio.comin𝕏

Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer.

BiotechHealthtech

Juan Jaen(Co-founder & President)inTerry Rosen(Co-founder & Chief Executive Officer)inBob Goeltz(Chief Financial Officer)inRichard Markus(Chief Medical Officer)inCarolyn Tang(General Counsel)Yvonne Gehring(SVP, Human Resources)

Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalGV (Google Ventures)SLVC+4 more

Ardelyxardelyx.com𝕏

Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs.

BiotechFremont, US

Mark Kaufmann(Executive Officer)Elizabeth Grammer(Executive Officer)inDavid Rosenbaum(Executive Officer)inJeremy Caldwell(Executive Officer)Mike Raab(Executive Officer, Director)in

BoardDavid Mott(Director)

Co-investorsHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)

Arriventarrivent.cominDec 2022

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCatalio Capital Management, LPGeneral CatalystHBM Healthcare InvestmentsHBM PartnersHongShan Capital GroupLAV+4 more

Ascendis Pharma A/Sascendispharma.comin𝕏Nov 2014

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in

Co-investorsVivo CapitalAisling CapitalAvoro Capital AdvisorsRA CapitalSofinnova PartnersSofinnova Ventures

Avenzoavenzotx.cominNov 2024

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

BiotechSan Diego, US

Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in

BoardCarl Gordon(Director)

Co-investorsDelos CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMedQuan Capital+6 more

Blueprint Medicinesblueprintmedicines.comin𝕏

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-Prime CapitalNextech InvestRA CapitalRidgeback CapitalWellington ManagementThird Rock Ventures

Bridgebiobridgebio.comin𝕏

BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.

BiotechHealthtech

Neil Kumar(Founder)

Co-investorsAisling CapitalAmzak HealthEcoR1 CapitalFrazier Life SciencesHEALTHCARE ROYALTY PARTNERSLongwood Fund+2 more

Candid Therapeuticscandidrx.cominAug 2024

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsLifeSci Venture PartnersOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesvenBio Partners+2 more

Careguidecareguide.comin𝕏Seed · Oct 2014 · $2M

CareGuide operates online marketplaces that connect people seeking care services with qualified caregivers across various verticals including pet care, home services, and childcare.

ConsumerDigital HealthHealthtechHR TechMarketplacesSaaSToronto, US

John GreeninAli Dinani(Chief Executive Officer)inKen Scott(Chief Financial Officer)inEmir Hasanbegovic(Chief Technology Officer)in

BoardJesse Rasch

Co-investors500 GlobalGarage CapitalInovia CapitalStructure CapitalFJ LabsOnStartups+1 more

Centessa Pharmaceuticalscentessa.com

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsAdvent Life SciencesEcoR1 CapitalGeneral AtlanticLifeSci Venture PartnersMedicxiOberland Capital+4 more

Chimagen Bioscienceschimagen.comin

Chimagen Biosciences is a Shanghai-based clinical-stage biotech developing multi-specific antibody therapeutics, including T-cell and NK-cell engagers, for cancer and autoimmune diseases.

ClipDropclipdrop.co𝕏Seedacquired by Stability AI

Clipdrop offers AI-powered image editing tools including background removal, object cleanup, image upscaling, and text-to-image generation.

AI & Machine LearningConsumerCreator EconomyMedia & EntertainmentSaaSParis, FR

Cyril Diagne(Founder)inJonathan Blanchet(Founder)inDamien Henry(Founder)in

Co-investorsAir Street CapitalKima VenturesSoma CapitalY CombinatorAmplify PartnersHarvard Management Company

Cogramcogram.cominSeed

Cogram builds AI-powered software tools for architects and engineers to automate documentation, reporting, and information retrieval from construction and architectural projects.

AI & Machine LearningConstruction TechEnterprise SoftwareFuture of WorkSaaSNew York City, US

Alexander von Boetticher(Founder)inRicardo Wölker(Founder)inFran Gonzalez(Engineering Manager)

Co-investorsCreative Destruction Lab (CDL)JovonoPioneerSoma CapitalY CombinatorAmplify Partners+8 more

Color Healthcolor.comin𝕏

Color Health operates a nationwide virtual cancer clinic delivering oncologist-led care, screening, and treatment management for employer, union, health plan, and public sector populations.

AI & Machine LearningDigital HealthHealthtechSan Francisco, US

Othman Laraki(Founder)inElad Gil(Founder)Nish Bhat(Founder)Taylor Sittler(Founder)

Co-investors8VCAliya Capital PartnersComcast VenturesCRV (Charles River Ventures)Dria VenturesGeneral Catalyst+14 more

ConnectiveRxconnectiverx.comin

ConnectiveRx provides hub services, patient support, and patient affordability programs that help pharmaceutical manufacturers, healthcare providers, and patients access and stay on prescribed therapies.

Digital HealthHealthtechSaaS

Co-investorsGenstarBlackstoneGenstar Capital

Corvus Pharmaceuticalscorvuspharma.cominSep 2015

Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.

BiotechHealthtechBurlingame, US

Richard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in

BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Co-Founder)inTerry G. Gould(Director)

Co-investorsAvoro Capital AdvisorsOrbiMed

Crossover Healthcrossoverhealth.comin𝕏

Crossover Health operates an integrated primary care delivery model centered on member experience, using proprietary technology and care structures to expand healthcare access and accountability.

Digital HealthHealthtech

Ryan Smith

Co-investorsNorwest Venture Partners

Cue Healthcuehealth.com

Covid test maker that went public at a $2.3 billion valuation.

Clint Sever(Founder)in

Co-investorsACME CapitalDarwin CapitalDecheng CapitalDentsu VenturesMothership VCPrime Partners+4 more

Cymabaycymabay.comin𝕏Aug 2015

Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.

BiotechHealthtechMedical DevicesNewark, US

Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)

BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in

Co-investorsAvoro Capital AdvisorsBay City CapitalVantagePoint Capital PartnersAbingworth

Delfi Diagnosticsdelfidiagnostics.comin

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

Victor Velculescu(Founder)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSusan Tousi(Chief Executive Officer)in

Co-investorsAV8 VenturesIllumina VenturesInitiate Venture PartnersMenlo VenturesMerck Global Health Innovation FundMSD Global Health Innovation Fund+7 more

Dermiradermira.com

HealthtechMenlo Park, US

Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)

BoardFred Craves(Director)in

Co-investorsAisling CapitalBay City CapitalCanaan PartnersNew Enterprise Associates (NEA)Fidelity InvestmentsQiming Healthcare+1 more

Dnanexusdnanexus.comin𝕏Apr 2015 · $58M

DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis.

AI & Machine LearningBiotechCloud ComputingData & InfrastructureMountain View, US

Andreas Sundquist(Founder)inSerafim Batzoglou(Founder)inRichard Daly(Executive Officer, Director)inGeorge Asimenos, PhD(Chief Product Officer)inArend Sidow(Founder)

BoardMichael Goldberg(Director)

Co-investorsClaremont Creek VenturesGV (Google Ventures)K9 VenturesSaints CapitalUncork CapitalWireframe Ventures

Eidos Therapeuticseidostx.com𝕏Mar 2018Acquired

A digital health resource platform providing medical professionals with educational information and clinical resources about transthyretin amyloid cardiomyopathy (ATTR-CM) and related cardiac and neurological conditions.

BiotechDigital HealthHealthtechSan Francisco, US

NEIL KUMAR(Executive Officer, Director)JONATHAN FOX(Executive Officer)UMA SINHA(Executive Officer)CHRISTINE SIU(Executive Officer)HOYOUNG HUH(Director)ERIC AGUIAR(Director)

Co-investorsAisling CapitalRA CapitalViking GlobalViking Global Investors

Elementelement.comin

Element Materials Technology provides materials testing, product qualification, and assurance services for customers in aerospace, space, defense, and energy sectors.

Advanced ManufacturingDeep TechDefense TechEnterprise SoftwareMedical DevicesNew Materials

Rick Sluiters(CEO of Element Aero, Space & Defense)

Co-investors3i GroupMetaplanetProtocol LabsT. Rowe PriceVenrock

Elementelement.market𝕏

Element is an NFT marketplace on Ethereum where users can create, swap, and trade NFT collections, with real-time floor price and volume data tracking.

Crypto & Web3Marketplaces

Co-investorsBitDAOMantle NetworkMetaplanetProtocol LabsT. Rowe PriceVenrock

Elementtryelement.de

Element modernizes legacy mainframe systems using its Global Context Engine, which performs deterministic analysis of a codebase to extract system infrastructure, data flows, and business logic as a foundation for modular transformation.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareParis, FR

Alexander Wiener(CEO)inLukas Marienfeld(CTO)in

Co-investorsEntrepreneur FirstProject EuropeTranspose Platform ManagementAutomatticDCVC (Data Collective)Hanwha Asset Management+6 more

Element Bioscienceselementbiosciences.comin𝕏Series C · Jun 2021 · $280M

Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions.

BiotechDeep TechHardwareMedical Devices

Matthew Kellinger(Founder)Michael Previte(Founder)Molly He(Founder)

Co-investorsDraper AssociatesFusionRA CapitalTSVCVenrockWellington Management

Everly Healtheverlywell.comin𝕏Dec 2020 · $175M

Everlywell offers at-home lab testing kits and virtual healthcare services across multiple wellness categories including daily health screening, digestive analysis, sexual health testing, and hormone monitoring.

ConsumerDigital HealthHealthtechWellness & Fitness

Julia Cheek(Founder & CEO)in

Co-investorsAnsa CapitalBreyer CapitalCerity Partners VenturesHalogen Ventures Management Company LlcLux CapitalNext Coast Ventures+12 more

Evidenceevidence.devin𝕏Seed

Evidence is a browser-based IDE for building interactive data dashboards and reports using SQL and markdown, with AI-powered development tools and support for multiple database backends.

AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareToronto, CA

Adam McAskill(Founder)inSean Hughes(Founder)inUdesh Senaratne(Engineer)Archie Wood(Head of Community)Brian Donald(Engineer)Charles Hardy(Engineer)

Co-investorsA.Capital VenturesY CombinatorASDF VenturesNextView VenturesNVP CapitalSV Angel

Fabric Genomicsfabricgenomics.comin𝕏

Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesOakland, US

Martin Reese(Co-Founder, President, and CEO)inMartin Reese, Ph.D.(Co-Founder, President, and CEO)Erwin Frise(Vice President of Technology and Data Science)in

Co-investorsArtis VenturesMighty CapitalCasdin Capital

Fibrogenfibrogen.comin𝕏Nov 2014

Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions.

BiotechHealthtechSan Francisco, US

Thomas B. Neff(Executive Officer, Director)Frank H. Valone(Executive Officer)inK. Peony Yu(Executive Officer)inPat Cotroneo(Executive Officer)inRory Riggs(Founder)

BoardRory B. Riggs(Director)

Co-investorsAvalon BioVenturesRidgeback CapitalScientia VenturesMaverick Ventures

Folxfolxhealth.comin𝕏Oct 2022 · $30M

FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.

Digital HealthHealthtechBoston, US

A.G. Breitenstein(Founder)inLena Ballantine(Executive Officer)inLiana M Guzman Weis(Executive Officer, Director)

BoardLynne Chou O'Keefe(Director)inMorgan Cheatham(Director)inLee Shapiro(Director)in

Co-investors7wire VenturesBessemer Venture PartnersCorewell Health VenturesDefine VenturesHabitat PartnersSeae Ventures+2 more

Foresight Diagnosticsforesight-dx.comin𝕏Series B · Apr 2023 · $59Macquired by Natera · Dec 2025 · $424.5M

Foresight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types.

BiotechDigital HealthHealthtechBoulder, US

Ash Alizadeh(Founder)David Kurtz(Founder)Jake Chabon(Founder)Maximilian Diehn(Founder)

Co-investorsAgent CapitalBoulder VenturesCivilization Ventures Management, LlcCU Healthcare Innovation FundPear VC

Galileogalileo.ioin

Galileo operates a medical practice combining a technology platform with in-house primary and multi-specialty clinicians to provide accessible, lower-cost care.

Digital HealthHealthtech

Tom X Lee(Founder)inTom Lee(CEO)

Co-investors8VCGaingelsLifeforce CapitalMcKesson VenturesNat TurnerNext Coast Ventures+8 more

Galileogalileo.aiin𝕏acquired by Cisco · Apr 2026

Splunk Agent Observability is a platform that monitors and secures AI agents in production by combining evaluation, observability, cost tracking, and guardrails.

AI & Machine LearningDeveloper ToolsEnterprise SoftwareSaaS

Vikram Chatterji(Founder)inAtindriyo Sanyal(Founder)inYash Sheth(Founder)inClay Wilkes(Founder)Dave Wilkes(Founder)

Co-investorsBattery VenturesCategory VenturesFPVPremji InvestS VenturesScale Venture Partners+10 more

GeekWiregeekwire.comin𝕏

GeekWire is a technology news and media company that covers the tech industry with a focus on the Seattle region and broader startup ecosystem.

Enterprise SoftwareMedia & EntertainmentSeattle, US

John Cook(Founder)Todd Bishop(Founder)Jonathan Sposato(Founder)John C. Cook(Founder)

Generation Biogenerationbio.comFeb 2018 · $100M

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsAtlas VentureWellington ManagementCasdin CapitalDeerfield Management CompanyF-Prime CapitalFidelity Investments+1 more

Genomicsgenomics.cnMar 2021 · $30M

BGI (Huada) is a genomics research and services organization offering clinical genetic testing, scientific research services, forensic/judicial testing, and sequencing instruments.

BiotechDeep TechDigital Health

Wang Jian(Founder)

Co-investorsF-Prime CapitalGreen Pine Capital Partners

Genomics Plcgenomics.comin𝕏

Genomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers.

AI & Machine LearningBiotechDigital HealthHealthtechOxford, GB

Peter Donnelly(Founder)inDr Chris Spencer(Founder)Dr Gerton Lunter(Founder)Gilean McVean(Founder)Professor Gil McVean(Founder)Professor Sir Peter Donnelly(Founder)

Co-investorsF-Prime CapitalOxford Science EnterprisesSalica InvestmentsIP Group

Glitziglitzi.com.mxin𝕏Seed

Glitzi is a service marketplace platform in Mexico that connects users with beauty and wellness professionals for on-demand services including hairstyling, massage, and facials.

ConsumerMarketplacesMexico City, MX

Ana Ramos(Founder)inLuis Enrique Vazquez(Founder)in

Co-investorsGaingelsY CombinatorAct One VenturesBeagle VenturesGanas VenturesGoodwater Capital+4 more

Googlegoogle.comin

Google operates the dominant web search engine and its advertising business, alongside Android, YouTube, Google Cloud and the Gemini AI models.

AI & Machine LearningMountain View, US

Larry Page(Founder)Sergey Brin(Founder)Sundar PichaiinOmar Hamoui(Founder)Dick Costolo(Founder)Aamir Virani(Founder)

Co-investorsKleiner PerkinsSilver Lake PartnersSV AngelWestern Technology Investment83NorthAccel+9 more

Hims & Hershims.com

US direct-to-consumer telehealth company selling prescription and OTC treatments online by subscription; NYSE-listed as HIMS.

Jack Abraham(Founder)inAndrew Dudum(Founder)Hilary Coles(Founder)Joe Spector(Founder)

Co-investors7GC & Co8VCA-Rod CorpAtomicBeta CapitalBling Capital+24 more

identifeye HEALTHidentifeye.healthin

Identifeye provides a fundus imaging platform combining a portable camera device and cloud-based portal software for retinal screening in point-of-care settings.

AI & Machine LearningDigital HealthHealthtechMedical Devices

ImmPACT Bioimmpact-bio.comSeries B · Jan 2022 · $140M

Co-investorsDecheng CapitalvenBio Partners

Inscriptainscripta.com

BiotechBoulder, US

Michael Graige(Executive Officer)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)Kevin Ness(Founder)inRyan Gill(Founder)

Co-investorsiGlobe PartnersKorysOak HC/FTOMX VenturesPaladin Capital GroupSpruce Capital Partners+4 more

Insitroinsitro.comin𝕏Mar 2020 · $143M

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

Daphne Koller(Founder)inDuane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in

BoardRobert Nelsen(Director)Vijay Pande(Director)in

Co-investorsAndreessen HorowitzARCH Venture PartnersDeviation CapitalGV (Google Ventures)HOF CapitalSoftBank Vision Fund+9 more

Intarcia Therapeuticsintarcia.comDec 2016

Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.

BiotechBoston, US

James Ahlers(Executive Officer)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Thomas Alessi(Executive Officer)Owen Hughes, Jr.(Executive Officer)

Co-investorsBay City CapitalCloudStone CapitalCycad Group LLCMarkerNXT VenturesAlta Partners+3 more

Ivantis Incivantisinc.comJan 2017Acquired

Ivantis was a medical device company founded in 2007 in Irvine, California, that developed the Hydrus Microstent, a minimally invasive device for treating glaucoma during cataract surgery.

Irvine, US

David Van Meter(Executive Officer, Director)

BoardTara Butler(Director)Douglas Roeder(Director)Ali Behbahani(Director)inRandy Alexander(Director)Thong Yuen Poon(Director)

Co-investorsAscension VenturesRA CapitalMemorialCare Innovation FundNew Enterprise Associates (NEA)

Jade Biosciencesjadebiosciences.comin

Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease.

BiotechHealthtech

Co-investorsFrazier Life Sciences

Karyopharm Therapeuticskaryopharm.comin𝕏Dec 2022

Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.

BiotechHealthtechNewton, US

Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)inReshma Rangwala(Executive Officer)inRichard Paulson(CEO)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in

Co-investorsAvoro Capital AdvisorsHEALTHCARE ROYALTY PARTNERSRA Capital

Khartis Therapeuticskhartis.cominSeries A · Jan 2024 · $45M

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.

BiotechMedical Devices

Co-investorsNextech InvestAlexandriaLilly Asia VenturesLongwood Fund

Kira Pharmaceuticalskirapharma.comin

Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases.

BiotechHealthtechCambridge, US

Wenru Song(Founder)in

Co-investorsQuan CapitalVivo CapitalIkarian Capital

Kriyakriya.coinMay 2022 · $270M

Kriya provides working capital loans and business finance products to UK and European businesses, helping them manage cash flow, fund wholesale orders, and scale their buyer base.

FintechSaaS

Anil Stocker(Founder)inCharles Delingpole(Founder)Ilya Kondrashov(Founder)

Co-investorsMouro CapitalNorthzoneBluebird VenturesHolland CapitalJDRF T1D FundNarya Capital+3 more

Kriya Therapeuticskriyatherapeutics.comin𝕏Jun 2021 · $1.2B

Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.

BiotechHealthtechMorrisville, US

Roger Jeffs(Co-Founder and Vice Chairman)inFraser Wright(Scientific Co-Founder and Chief Gene Therapy Officer)inShankar Ramaswamy(Founder)inMichele Stone(Chief Scientific Officer)inKatherine Eade(Chief Legal Officer)Britt Petty(Chief Manufacturing Officer)in

Co-investorsPatient Square CapitalPremji InvestAlumni VenturesAmplo VenturesAnjostBluebird Ventures+3 more

Kythera Biopharmaceuticalsallergan.comAcquired

Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.

Allen Chao(Founder)

Co-investorsAisling CapitalARCH Venture PartnersMESA VERDE VENTURE PARTNERSProspect Venture PartnersSchooner CapitalALTITUDE LIFE SCIENCE VENTURES+2 more

Latigo Biolatigobio.comSeries A · Jan 2025 · $140M

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.

BiotechHealthtechMedical DevicesThousand Oaks, US

Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)Sean Harper Desmond Padhi(Founder)

BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inDeborah Palestrant(Director)in

Co-investors5AM VenturesAccess BiotechnologyAscenta CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners

LifeMine Therapeuticslifeminetx.cominSep 2017

LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.

AI & Machine LearningBiotechDeep TechCambridge, US

Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.

BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)

Co-investorsARCH Venture PartnersGV (Google Ventures)RA CapitalAisling CapitalAlexandriaBezos Expeditions+7 more

Lightdashlightdash.comin𝕏Seed

Lightdash is an open-source business intelligence tool that natively supports dbt metrics and analytics workflows.

AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareLondon, GB

Hamzah Chaudhary(Founder)inOliver Laslett(Founder)inJose Rego(Software Engineer)

Co-investorsAccelMoonfire VenturesOutlier GroveY CombinatorAccuro TrusteesCharles Delingpole+5 more

Lovagegetlovage.comin𝕏Seed

Lovage automatically generates and posts social media content about open appointment slots for beauty professionals, helping them convert availability into client bookings using AI-generated designs.

AI & Machine LearningEnterprise SoftwareMarketing TechSaaSOrem, US

Austin Petersen(Founder)inRobert Hinckley(Founder)inAlexander Steffen(Founder)inBoyd Christiansen

Co-investorsCampus Founders FundY CombinatorAmino CapitalConvoi VenturesD Global VenturesPeterson Venture Partners+2 more

Lucira Healthlucirahealth.comin

Lucira Health manufactures portable diagnostic devices that connect to smartphones to test bodily fluids for infectious diseases, enabling rapid results outside of clinical settings.

BiotechHealthtechMedical DevicesEmeryville, US

Debkishore Mitra(Founder)inJohn R. Waldeisen(Director)John Waldeisen(CEO)Ivan Dimov

BoardErik T. Engelson(Executive Officer, Director)Justin Butler(Director)

Co-investors11.2 CapitalShangBay Capital LLCY CombinatorDCVC (Data Collective)DHVCEclipse Ventures+4 more

Lyelllyell.cominMar 2020

Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.

BiotechDeep TechHealthtechMedical DevicesBothell, US

Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)

Co-investorsARCH Venture PartnersvenBio Partners8VCAxial VC

Lyellbiotechlyellbiotech.com

Lyell Immunopharma is a Nasdaq-listed cell therapy developer engineering T cell therapies for solid tumors and blood cancers.

Co-investorsARCH Venture PartnersAxial VC

Mammoth Biosciencesmammoth.bioin𝕏Nov 2020

Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.

BiotechDeep TechMedical DevicesBrisbane, US

Jennifer Doudna(Founder)inTrevor Martin(Founder)inJanice Chen(Founder)inLucas Harrington(Founder)inAshley Tehranchi(Founder)in

BoardUrshit Parikh(Director)

Co-investors8VCBerkeley FrontierCalifornia Innovation FundDecheng CapitalMayfield FundMission Bay Capital+12 more

Midi Healthjoinmidi.cominFeb 2026 · $100M

MIDI develops digital health solutions for patients and clinicians to improve access to and delivery of care across diverse populations.

Digital HealthHealthtechLos Altos Hills, US

Joanna Stober(Executive Officer, Director)Sharon Meers(President & Co-founder)inJoanna Strober(Founder)inKathleen Jordan MD(Chief Medical Officer & Co-founder)inKathleen Jordan(Founder)

BoardAllison Gates(Director)in

Co-investors1843 Capital25MadisonAble PartnersAdvance Venture PartnersAvestria VenturesCity Light+19 more

Mirviemirvie.cominJul 2025 · $60M

Mirvie develops an RNA-based platform for early detection of pregnancy complications, enabling proactive intervention before complications become critical.

BiotechFemTechHealthtechSouth San Francisco, US

Maneesh Jain(Founder)inStephen Quake(Founder)

BoardLisa Iverson(Director)Ursheet Parikh(Director)inMin Cui(Director)inSamir Kaul(Director)in

Co-investorsCorrelation VenturesDecheng CapitalGaingelsGeneral CatalystGV (Google Ventures)Mayfield Fund+3 more

Myomemyome.comin𝕏

MyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.

BiotechDigital HealthHealthtechMedical Devices

Akash Kumar(Chief Medical and Scientific Officer / Co-Founder)inKate Im(Senior Vice President of Research / Co-Founder)in

Co-investorsHOF CapitalSamsung NextSequoia Capital

Mythic Therapeuticsmythictx.comDefunct

Mythic Therapeutics was a clinical-stage biotech developing next-generation antibody-drug conjugates for cancer using its proprietary FateControl technology.

BiotechWaltham, US

Brian Fiske(Executive Officer, Director)George Eliades(Executive Officer, Director)inSandra Poole(Executive Officer)inAlex Nichols(Executive Officer, Director, Promoter)

BoardBryan Roberts(Director)inPeter Hecht(Director)

Co-investorsHemi Ventures, LlcLifeforce CapitalNat TurnerViking GlobalRefactor Capital

Nanostringnanostring.com𝕏acquired by Bruker · Apr 2024 · $392.6M

NanoString (part of Bruker Spatial Biology) develops instruments and assays for spatial biology and gene expression analysis, including single-cell and subcellular spatial transcriptomics, proteomics, and multiomics.

BiotechDeep TechHealthtechMedical Devices

Co-investorsAspect VenturesKicker VenturesOwl Capital

Nested Therapeuticsnestedtx.comin𝕏Oct 2022

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.

AI & Machine LearningBiotechHealthtech

Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)inDarrin Miles(Chief Executive Officer)inPhilip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)in

Co-investorsVersant VenturesSixty Degree CapitalCowen Healthcare InvestmentsGoldman SachsSection 32

Neurodermneuroderm.comin
Novavax, Inc. (Alumni)novavax.com

Novavax develops protein-based nanoparticle vaccines paired with its Matrix-M adjuvant to produce broad, long-lasting immune responses.

BiotechHealthtech

Nurix Therapeuticsnurixtx.comin𝕏

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)inMark Goldsmith(Director)

Co-investorsBain Capital Life SciencesEcoR1 CapitalGeneral AtlanticSofinnova VenturesThe Column GroupWellington Management+1 more

Odyssey Therapeuticsodysseytx.comin𝕏

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)Gary D. Glick, Ph.D.(Founder, President & CEO)

BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)

Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPGlobal BioAccess FundGreatPoint Ventures+9 more

Oncologyoncology.venturesSep 2026 · $125M

Oncology Ventures is a cancer-focused venture capital fund that invests in healthcare technology startups related to oncology care.

AI & Machine LearningBiotechDigital HealthHealthtech

Ben Freeberg(Founder, Managing Partner)inJay Freeberg(Chief Financial Officer)

Co-investorsSandwich CapitalAlleyCorpCanaan PartnersConcord Health PartnersCVS Health VenturesForbion+5 more

OptiNoseoptinose.com

Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists.

BiotechHealthtechMedical DevicesYardley, US

Per Djupesland(Executive Officer, Director)inMichele Janis(Executive Officer)Peter Miller(Executive Officer, Director)inTerrence Terifay(Executive Officer)Ramy Mahmoud(Executive Officer)in

BoardKlaas De Boer(Director)

Co-investorsAvistaMVM Life Science Partners

Orchard Therapeuticsorchard-tx.comin𝕏

Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.

BiotechDeep TechHealthtechMedical DevicesLondon, GB

Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)

BoardBobby Gaspar(Scientific Founder)in

Co-investorsAlbionVCF-Prime CapitalUCL Technology Fund4BIO CapitalAgent CapitalBaillie Gifford+3 more

Peloton Therapeuticspelotontherapeutics.comacquired by Merck · May 2019 · $2.2B

Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.

BiotechDigital HealthMedical Devices

Co-investorsCurative VenturesNextech InvestRidgeback CapitalThe Column GroupVida Ventures

Pharvarispharvaris.comin𝕏Series B · Sep 2019 · $66M

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsBain Capital Life SciencesGeneral AtlanticKurma PartnersvenBio PartnersViking Global

PicnicAIpicnic.aiin𝕏Series A

PicnicAI develops AI technology to support patient-centered clinical care and medical research.

AI & Machine LearningDigital HealthHealthtechSan Francisco, US

Noga Leviner(CEO)inTroy Astorino(CTO)inLuna Federici(Chief Executive Officer)inJustin Maslin(Software Engineer)Shannah Metz(Recruiter)Stephanie Iannello(Recruiting)

Co-investorsY CombinatorAmplify PartnersB Capital GroupFelicis VenturesGreat Oaks Venture CapitalMantis Capital+6 more

Pinnacle Medicinespinnaclemedicines.cominMar 2026

Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.

BiotechDigital HealthDoylestown, US

Chengzao Sun(Founder)inSandeep Somani(Founder)in

Co-investorsQuan CapitalRA CapitalLAVOrbiMedVenrock

Propellerpropeller.bio

Propeller Bio discovers and develops biologic therapeutics that target multiple disease-driving pathways to achieve synergistic effects, aimed at patients with unmet medical needs.

BiotechSan Francisco Bay Area, US

David W. Shen(Founder)in

Co-investorsOrbiMedBlackbird VenturesMcKesson VenturesSequoia Capital

Puma Biotechnology, Inc. (Alumni)pumabiotechnology.com

Puma Biotechnology is a biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for cancer treatment.

BiotechHealthtech

Quantum Siquantum-si.comin𝕏

Quantum-Si develops next-generation protein sequencing technology that enables single amino acid detection by combining biology, chemistry, artificial intelligence, and semiconductor technology.

BiotechDeep TechHardwareMedical Devices

Jeff Hawkins(CEO)inJeff Keyes(Chief Financial Officer)inChristian LaPointe(General Counsel)inTodd Rearick(Chief Technology Officer)inLindsay Thompson(Chief Human Resources Officer)in

Co-investorsHighCape CapitalYuanBio Venture Capital

RAPT Therapeuticsrapt.cominacquired by GSK · Jan 2026 · $2.2B

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.

BiotechHealthtech

Co-investorsFrazier Life SciencesGV (Google Ventures)Kleiner PerkinsMedicxiSolasta VenturesThe Column Group+1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Allergen ResearchFl2021-001Interline Therapeutics, Inc.Spear Bio89 Bio, Inc. (Alumni)Abdera TherapeuticsAcceleron PharmaAduro BiotechAllogene (Alumni)AudentesAvanir PharmaceuticalsAveXisBellicum PharmaceuticalsBiodelivery Sciences International CopyBioDelivery Sciences International, Inc. (Alumni)Biohaven PharmaceuticalCentessa Pharmaceuticals (Alumni)CopyDetect, Inc.Dyax CorpEngene Holdings IncEpizyme, Inc. (Alumni)Generation Bio (Alumni)Ikena Oncology, Inc.ImageneBio, Inc. (Alumni)Immpact Bio UsaImmunomedics, Inc. (Alumni)IndomoInterline TherapeuticsLundbeck Seattle Biopharmaceuticals IncModal Therapeutics Inc.Momenta Pharmaceuticals, Inc. (Alumni)MyokardiaNgm BiopharmaceuticalsObsidian Therapeutics, Inc.OlemaPhaxiam Therapeutics S APopulation Health Investment Co

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.